Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1324-1329

  Grigsby, Iwen F ^a,b   Pham, Lan ^a   Gopalakrishnan, Raj ^a   Mansky, Louis M ^a,b   Mansky, Kim C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AST; G protein; HAART; HIV; Osteoblast; snoRNA

Indexed keywords

ASPARTATE AMINOTRANSFERASE ISOENZYME 2; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA STIMULATING PROTEIN; SMALL NUCLEOLAR RNA; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE DENSITY; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; IN VITRO STUDY; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASE, MITOCHONDRIAL; BONE DENSITY; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOCLASTS; OSTEOPOROSIS; PHOSPHONIC ACIDS; RNA, SMALL NUCLEOLAR;

EID: 73949105375     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.039     Document Type: Article

References (29)

1. Cihlar T., Birkus G., Greenwalt D.E., and Hitchcock M.J. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54 (2002) 37-45
2. Birkus G., Hitchcock M.J., and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 716-723
3. Cossarizza A., and Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18 (2004) 137-151
4. Venhoff N., Setzer B., Melkaoui K., and Walker U.A. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. 12 (2007) 1075-1085
5. Castillo A.B., Tarantal A.F., Watnik M.R., and Martin R.B. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys. J. Orthop. Res. 20 (2002) 1185-1189
6. Van Rompay K.K., Brignolo L.L., Meyer D.J., Jerome C., Tarara R., Spinner A., Hamilton M., Hirst L.L., Bennett D.R., Canfield D.R., Dearman T.G., Von Morgenland W., Allen P.C., Valverde C., Castillo A.B., Martin R.B., Samii V.F., Bendele R., Desjardins J., Marthas M.L., Pedersen N.C., and Bischofberger N. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. 48 (2004) 1469-1487
7. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., Coakley D.F., Lu B., Toole J.J., and Cheng A.K. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
8. Gafni R.I., Hazra R., Reynolds J.C., Maldarelli F., Tullio A.N., DeCarlo E., Worrell C.J., Flaherty J.F., Yale K., Kearney B.P., and Zeichner S.L. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118 (2006) e711-e718
9. Purdy J.B., Gafni R.I., Reynolds J.C., Zeichner S., and Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J. Pediatr. 152 (2008) 582-584
10. Wactawski-Wende J., Grossi S.G., Trevisan M., Genco R.J., Tezal M., Dunford R.G., Ho A.W., Hausmann E., and Hreshchyshyn M.M. The role of osteopenia in oral bone loss and periodontal disease. J. Periodontol. 67 (1996) 1076-1084
11. Wactawski-Wende J. Periodontal diseases and osteoporosis: association and mechanisms. Ann. Periodontol. 6 (2001) 197-208
12. Mansky K.C., Marfatia K., Purdom G.H., Luchin A., Hume D.A., and Ostrowski M.C. The microphthalmia transcription factor (MITF) contains two N-terminal domains required for transactivation of osteoclast target promoters and rescue of mi mutant osteoclasts. J. Leukoc. Biol. 71 (2002) 295-303
13. Mansky K.C., Sankar U., Han J., and Ostrowski M.C. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J. Biol. Chem. 277 (2002) 11077-11083
14. Mansky K.C., Sulzbacher S., Purdom G., Nelsen L., Hume D.A., Rehli M., and Ostrowski M.C. The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter. J. Leukoc. Biol. 71 (2002) 304-310
15. Van Gelder R.N., von Zastrow M.E., Yool A., Dement W.C., Barchas J.D., and Eberwine J.H. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc. Natl. Acad. Sci. USA 87 (1990) 1663-1667
16. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., and Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
17. Barditch-Crovo P., Deeks S.G., Collier A., Safrin S., Coakley D.F., Miller M., Kearney B.P., Coleman R.L., Lamy P.D., Kahn J.O., McGowan I., and Lietman P.S. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45 (2001) 2733-2739
18. Boffito M., Pozniak A., Kearney B.P., Higgs C., Mathias A., Zhong L., and Shah J. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob. Agents Chemother. 49 (2005) 4386-4389
19. Kwak H.B., Kim J.Y., Kim K.J., Choi M.K., Kim J.J., Kim K.M., Shin Y.I., Lee M.S., Kim H.S., Kim J.W., Chun C.H., Cho H.J., Hong G.Y., Juhng S.K., Yoon K.H., Park B.H., Bae J.M., Han J.K., and Oh J. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol. Pharm. Bull. 32 (2009) 1193-1198
20. Moreau M.F., Guillet C., Massin P., Chevalier S., Gascan H., Basle M.F., and Chappard D. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem. Pharmacol. 73 (2007) 718-723
21. Castrop H., Oppermann M., Mizel D., Huang Y., Faulhaber-Walter R., Weiss Y., Weinstein L.S., Chen M., Germain S., Lu H., Ragland D., Schimel D.M., and Schnermann J. Skeletal abnormalities and extra-skeletal ossification in mice with restricted Gsalpha deletion caused by a renin promoter-Cre transgene. Cell Tissue Res. 330 (2007) 487-501
22. Sakamoto A., Chen M., Nakamura T., Xie T., Karsenty G., and Weinstein L.S. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J. Biol. Chem. 280 (2005) 21369-21375
23. Surendran S., Matalon K.M., Szucs S., Tyring S.K., and Matalon R. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease. J. Child Neurol. 18 (2003) 611-615
24. Desai V.G., Lee T., Delongchamp R.R., Leakey J.E., Lewis S.M., Lee F., Moland C.L., Branham W.S., and Fuscoe J.C. Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion 8 (2008) 181-195
25. Higa S., Yoshihama M., Tanaka T., and Kenmochi N. Gene organization and sequence of the region containing the ribosomal protein genes RPL13A and RPS11 in the human genome and conserved features in the mouse genome. Gene 240 (1999) 371-377
26. Gaspin C., Cavaille J., Erauso G., and Bachellerie J.P. Archaeal homologs of eukaryotic methylation guide small nucleolar RNAs: lessons from the Pyrococcus genomes. J. Mol. Biol. 297 (2000) 895-906
27. Omer A.D., Lowe T.M., Russell A.G., Ebhardt H., Eddy S.R., and Dennis P.P. Homologs of small nucleolar RNAs in Archaea. Science 288 (2000) 517-522
28. Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 20 (2001) 3617-3622
29. Matera A.G., Terns R.M., and Terns M.P. Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat. Rev. Mol. Cell. Biol. 8 (2007) 209-220